March 22, 2011

Roy S. Herbst, MD, PhD
Chief of Medical Oncology and Associate Director for Translational Research, Yale Cancer Center

**Personalized Therapy for Advanced NSCLC, Targeting KRAS Activated Pathways**

**Needs:** Lung cancer is the number one cause of cancer death. Personalized therapy represents a promising approach to making progress. However, mutant KRAS, which accounts for greater than 25% of cases, offers few treatment options. This lecture will explore new approaches for this refractory population.

**Objectives:** To become familiar with recent targeted therapy for NSCLC; to discuss biopsy approaches for lung cancer protocol therapy; and to understand the role of KRAS pathways in NSCLC.